Compare AOMR & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AOMR | TVRD |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.3M | 246.5M |
| IPO Year | 2021 | N/A |
| Metric | AOMR | TVRD |
|---|---|---|
| Price | $8.95 | $4.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 7 |
| Target Price | $11.13 | ★ $51.67 |
| AVG Volume (30 Days) | ★ 131.8K | 123.7K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | ★ 14.32% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $34,705,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.56 | N/A |
| P/E Ratio | $12.19 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.36 | $3.74 |
| 52 Week High | $10.88 | $43.65 |
| Indicator | AOMR | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 54.65 | 34.35 |
| Support Level | $8.67 | $4.05 |
| Resistance Level | $8.93 | $4.71 |
| Average True Range (ATR) | 0.14 | 0.27 |
| MACD | 0.05 | 0.55 |
| Stochastic Oscillator | 96.26 | 73.20 |
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.